Tomivosertib With Azacitide and Venetoclax for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia Who Are Not Suitable for Intensive Chemotherapy

• Status: Not yet recruiting
• Trial end date: 2030-04-23

Summary

This phase I/Ib trial tests the safety, side effects, and best dose of tomivosertib in combination with the standard treatment of azacitidine and venetoclax for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy. Tomivosertib may stop the growth of cancer cells and may kill them by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing them, stopping them from dividing, or by stopping them from spreading. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving tomivosertib with azacitide and venetoclax may kill more cancer cells in patients with newly diagnosed AML who are not suitable for intensive chemotherapy.

• Phase: Phase 1

Details

• Lead Sponsor: Northwestern University
• Collaborator: National Cancer Institute (NCI)
• Treatments: Azacitidine; Venetoclax